A study of nearly 1,500 patients treated for kidney cancer at UCLA in the last 15 years shows that an aggressive, tailored treatment approach results in better survival rates and uncovered subsets of kidney cancer that behave differently and need to be treated accordingly.

The results of a phase III, randomized clinical study involving patients with advanced renal cell carcinoma and poor prognostic features show temsirolimus improved overall survival when compared to the current treatment for this stage of disease. The study, led by Gary R. Hudes, M.D., director of the Genitourinary Malignancies Program at Fox Chase Cancer Center, is published in the May 31 issue of the New England Journal of Medicine. Jun 1, 2007 - 4:00:00 AM

Using newly available data on worldwide cancer incidence to map cancer rates in relation to proximity to the equator, researchers at the Moores Cancer Center at University of California, San Diego (UCSD) have shown a clear association between deficiency in exposure to sunlight, specifically ultraviolet B (UVB), and kidney cancer. Sep 19, 2006 - 2:53:00 PM

According to a new study, the drug sunitinib malate is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma (mRCC). Jun 5, 2006 - 4:34:00 PM

Bayer AG said Friday that the company and its US partner Onyx Pharmaceuticals Inc have received a positive response from European officials to their drug to treat kidney cancer.Apr 30, 2006 - 7:25:00 PM

Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal stromal cancers (GISTs), is not likely to be effective for patients with high grade renal cell carcinoma -- the most aggressive kidney cancer. Results of the study are published in the January issue of The Journal of Urology.Dec 22, 2005 - 5:04:00 AM